Beta Preserve
Principal Investigator:
Study sponsor: Sanofi
Location: International Diabetes Center
Phase of Study: III
Purpose of study: This study is looking at how an investigational study drug, called teplizumab, might possibly help protect insulin-producing cells by affecting the immune cells that attack them. The main goal of the study is to see if teplizumab can work better than a placebo (a look alike with no medicine in it) in helping people keep their blood sugar in a healthy range or use less mealtime insulin. Teplizumab is already FDA approved for use in earlier-stage of type 1 diabetes.
Inclusion Criteria:
To join this study, participants must:
– Be 18 to 25 years of age
– Have been recently diagnosed (within a month) with type 1 diabetes.
– Be positive for at least one T1D autoantibody (proteins that attack insulin-making cells by mistake).
Other criteria may also apply.
Participants will receive all study-related medical care at no cost and will be closely monitored by a doctor throughout the study.
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
